Biotechs are saving the world from superbugs. Can they also save themselves?

  15 June 2021

The world is now heavily reliant on small- and medium-sized enterprises (SMEs) to bring life-saving new antibiotics and antifungals to market. Accounting for 75% of all late-stage antibiotics and antifungals in development, they are pivotal in driving new antimicrobial innovation. Yet despite this, these smaller companies often face funding shortfalls and bankruptcy, leaving promising new drugs stranded on the lab bench. This report identifies how a crop of SMEs are finding new ways to survive and bring their life-saving medicines successfully through the pipeline. 

Author(s): Access to Medicine Foundation
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin